Clifford Chance‘s healthcare and life sciences practice impresses with a diverse advisory offering, which consists of transactions, regulatory and compliance as well as healthcare technology. The team includes experts from various disciplines, such as data and corporate law, and advises major international pharmaceutical, medical device and healthcare companies, which also benefit from the firm’s international network. Among the most recent instructions was the support in large-volume transactions, the design of supply and distribution systems for medicinal cannabis as well as the advice on ESG-related matters; the team also took the lead in constitutional complaint proceedings against the temporary increase in the general manufacturer’s discount for pharmaceuticals. Since May 2024, the group is led by Peter Dieners (compliance), Ulrich Reese, Gunnar Sachs (healthcare technology), and Torsten Syrbe. The latter combines expertise in antitrust law with longstanding transaction support and regulatory competencies, while Reese is an expert in copyright issues and regularly advises on the advertising, distribution and reimbursement of medical devices and pharmaceuticals.
Testimonials
Collated independently by Legal 500 research team.
'Strong team in health law, which is characterized above all by decades of experience in this field and can implement this in a particularly pragmatic way. Creative solutions are part of the firm's standard tools. The full-service character of the firm provides the security and comfort of receiving overall strategic advice for every inquiry.'
'Gunnar Sachs is always available with dedication and goes the extra mile for every request to achieve positive results for the client. On a personal level, it is always a pleasure to work with him. He is supported by a great team of associates who are technically excellent and, in combination with the partners' many years of experience, form a top team.'
Key clients
- Ipsen Pharma und JanssenCilag Pharma GmbH
- Abbott Laboratories Inc.
Work highlights
- Filing of a constitutional complaint for Ipsen Pharma GmbH and Janssen Cilag Pharma GmbH against provisions of the Statutory Health Insurance Financial Stabilization Act and the Drug Supply Shortages Control and Supply Improvement Act.
- Advising Pfizer Inc. on the legal integration of Global Blood Therapeutics into Pfizer structures in various European countries following the acquisition of the company.